Results: A significant correlation between serum HBsAg quantitation level and HBV DNA levels was revealed in all studied HBeAg negative patients (r =0.748, P= <0.001). A significant correlation between serum HBsAg level and fibrosis (r=0.334, P= 0.018). While, there is no significant correlation between serum HBsAg quantitation level and activity by Metaver scoring in all studied patients (P >0.05). Conclusion: All the studied patients were tested for assess correlation between HBsAg quantitation, HBV-DNA level and histopathology grading and staging. There is strong positive correlation between HBsAg quantation level and HBV-DNA and between HBsAg quantation level and stages of fibrosis. No correlation between HBV DNA levels and histopathology.

Background and study aim: Egypt has the highest prevalence of hepatitis C virus (HCV) infection in the world and is facing an epidemic of type 2 diabetes mellitus. The objective of this study was to assess the frequency of prediabetes in patients with chronic HCV infection. Subjects and Methods: A crosssectional study was performed on 60 HCV patients. Twenty healthy persons were taken as controls. Full history taking, clinical examination, routine laboratory and radiological investigations were done Body mass index (BMI), Waist Hip ratio, serum fasting glucose and fasting insulin were determined. IR was calculated by the Homeostasis Model for Assessment of Insulin Resistance (HOMA-IR), where values less than 2 has been considered completely normal and higher than 2 as a prediabetic state. Results: Serum fasting glucose, fasting insulin and HOMA-IR levels were significantly higher among HCV group compared with control group. The frequency of prediabetic (HOMA-IR values >2) among non-diabetic chronic HCV patients is 63.33%. Conclusion: Chronic HCV patients should be screened regularly for insulin resistance to avoid the double burden of diabetes mellitus and HCV.

Background: Hepatitis C Virus infects about 185 million people equating 2.8% of worldwide population and about 500,000 people die annually from hepatitis C related liver diseases. The most common clinical presentation of the disease is the chronic hepatitis and its complications such as: Compensated cirrhosis, portal hypertension, decompensated cirrhosis and Hepatocellular Carcinoma (HCC). Therapeutic management of chronic HCV patients traditionally depended on combination of peg-interferon (IFN) with ribavirin but this regimen showed many serious side effects beside its nonsatisfactory efficacy. In 2013, a second generation of Direct Acting Antiviral Agents (DAAs) gave a promising efficacy and safety. Although many IFN free regimens were approved, further evaluations are needed for these regimens. Aim: To compare sofosbuvir in combination with Daclatasvir, Ledipasvir and Simeprevir in patients with chronic hepatitis C infection according to safety, efficacy, relapse and patient outcomes. Patients and Methods: This is a prospective study conducted on 150 patients of chronic HCV who were admitted to the Viral Hepatitis Center in Al-Ahrar Educational Hospital in Zagazig {National Committee for the Control of Viral Hepatitis (NCCVH) during the first 9 months of 2017 and were selected according to the inclusion and exclusion criteria set by the (NCCVH). 58% of overall participants had cirrhosis and 2.7% were treatment-experienced. Patients were assigned into three groups: 50 patients received Sofosbuvir + Daclatasvir ± Ribavirin (SOF/DCV ± RBV) therapy, 50 patients received Sofosbuvir + Ledipasvir ± Ribavirin (SOF/LDV ± RBV) therapy and 50 patients received Sofosbuvir + Simeprevir ± Ribavirin (SOF/SIM±RBV) therapy. Three regimens were given for 12 weeks. Primary end point was the rate of achieving SVR12 by HCV RNA PCR, while secondary end point was the occurrence of virologic relapse.

Background and study aim: Nonalcoholic fatty liver disease (NAFLD) has an increasing prevalence worldwide. It has also been closely associated with obesity and metabolic syndrome-two conditions known to be associated with ischemic heart disease (IHD). The aim of this study was to assess the association between NAFLD and ischemic heart disease. Subjects and Methods: 140 patients with NAFLD and 70 non-NAFLD subjects were selected. Full history taking, clinical examination and laboratory tests including blood sugar, lipid profile and liver profile were done. Ultrasonography was performed to prove NAFLD while ECG and echocardiography were used for detection of myocardial ischemia. Results: Of the NAFLD group, the frequency of mild, moderate and severe NAFLD was 42.9%, 30% and 27.1% respectively. Subjects with NAFLD had a significantly higher BMI, waist circumference and weight compared to those of non NAFLD group (p=0.014, 0.0218 and <0.001 respectively). Independent risk factors for NAFLD were obesity, DM,

No abstract